Skip to content
Elmiron Lawsuit

Elmiron Lawsuit

Elmiron is used to treat the urinary condition, interstitial cystitis. Up to 25% of people who took Elmiron long-term may suffer from a unique type of ocular damage called pigmentary maculopathy. People who developed eye damage after taking Elmiron may be eligible for compensation.

Open, accepting new clients
Free Consultation - No Obligation

Complete this form and we’ll get in touch within 24 hours.

Name(Required)
State(Required)

By submitting this form I agree to the terms of SeegerWeiss.com Disclaimer and Privacy Policy.

This field is for validation purposes and should be left unchanged.

Our Role

Seeger Weiss partner Parvin Aminolroaya was appointed as co-lead counsel in the Elmiron multidistrict litigation by U.S. District Court Judge Brian Martinotti in January 2021. She represents users of the interstitial cystitis medication who allege they suffered eye injuries, such as pigmentary maculopathy, due to use of the drug. Aminolroaya heads up a team of experienced litigators leading the efforts to hold Janssen Pharmaceuticals and Teva Branded Pharmaceutical accountable.

Case Updates

  • 3/9/22

    As of March 9, 2022, 803 cases alleging products liability claims relating to use of Elmiron have been filed and served (712 federal and 91 in state courts).

  • 10/6/21

    Judge Martinotti outlined the guidelines and procedures for selecting bellwether cases in Case management order 17. On or before Nov. 15, plaintiffs and defendants will each select 10 cases to undergo case-specific discovery for a total of 20 Bellwether Discovery Cases. From the pool of 20 cases three will be selected – one each by the Plaintiffs’ Executive Committee, Defendants’ Lead Counsel, and the Court – for expert discovery. Once discovery is completed, each of the three bellwether cases will go to trial.

  • 5/13/21

    In Case Management Order 9, Judge Martinotti instituted a preliminary plan for discovery in the Elmiron MDL, ordering general discovery to go through the Plaintiff co-lead counsel and limiting case-specific discovery to completing Plaintiff Fact Sheets and Defendant Fact Sheets. Notably, the Judge said that the first bellwether trial will be held around January 2023, with subsequent bellwether trials to follow.

  • 1/22/21

    Seeger Weiss partner Parvin K. Aminolroaya was appointed by the honorable Judge Brian R. Martinotti to the position of plaintiffs’ co-lead counsel in the In re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation. Aminolroaya was selected for inclusion in National Law Journal’s Rising Stars for 2021, which is issued by ALM, and was included on lists of the Lawdragon 500 Leading Plaintiff Consumer Lawyers, which is issued by Lawdragon Inc., and Best Lawyers in America as published by U.S. News & World Report. She has previously worked on other major MDLs, including In re 3M Combat Arms Earplug Products Liability LitigationIn re National Prescription Opioid Litigation, and Testosterone Replacement Therapy (TRT) Products Liability LitigationLearn more here.

    No aspect of this advertisement has been approved by the Supreme Court of New Jersey. Learn more about legal award selection methodology here.

  • 12/15/20

    The Judicial Panel on Multidistrict Litigation (JPML) ordered pending Elmiron lawsuits centralized in the District of New Jersey before the Honorable Brian H. Martinotti.

  • 10/12/19

    A team of experienced ophthalmologists who conducted a review of patients at Kaiser Permanente in Northern California determined that up to 25% of patients using widely prescribed Elmiron for long-term treatment of symptoms associated with interstitial cystitis had developed a maculopathy, including pigmentary maculopathy. The ophthalmologists presented this evidence at the Annual Meeting of the American Academy of Ophthalmology.